selenious acid
Approved
Apr 30, 2019
Selenous acid is the chemical compound with the formula H2SeO3. Structurally, it is more accurately described by O=Se(OH)2. It is the principal oxoacid of selenium; the other being selenic acid. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 13 marketing orgs
Earliest trial started Dec 1, 2010 (NCT01141556)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
- Apr 30, 2019
American Regent, Inc. — Earliest FDA Approval
- Apr 30, 2019
Sankyo — Marketing Organization
- Apr 30, 2019
American Regent, Inc. — NDA Organization
- Apr 30, 2019
Daiichi Sankyo — NDA Secondary Org
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
- Feb 10, 2025
Fresenius — Marketing Organization
- Feb 20, 2025
Sun Pharmaceuticals — Marketing Organization
- Apr 28, 2025
STERISCIENCE — Marketing Organization
- Jun 11, 2025
Aspiro — Marketing Organization
- Jul 8, 2025
Gland Pharma Ltd — Marketing Organization
- Jul 21, 2025
Cipla — Marketing Organization
- Dec 31, 2025
Apicore — Marketing Organization
- Dec 31, 2025
STIRA — Marketing Organization
- Jan 7, 2026
BPI — Marketing Organization
- Feb 3, 2026
KINDOS — Marketing Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Supplement
Nutritional supplement.
- Unspecified targetAntioxidant
antioxidant
Combination products
multrys
with cupric sulfate pentahydrate, zinc dichloride, manganese sulfate
Approval history
- approvedPriority reviewFast trackApr 30, 2019
Chemistry & pharmacology
SMILES
O=[Se](O)O- Mol. weight
- 128.97 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaSelenous acid ↗
- ChEMBLCHEMBL2009089 ↗
Also known as
- selenase
- selenious acid
- selenious acid
- selenious acid
- selenous acid
- selenous acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05661682 | Phase 4 | Sep 30, 2023 | American Regent, Inc. |
| NCT05677126 | Phase 4 | Sep 30, 2023 | American Regent, Inc. |
| NCT04869579 | Phase 2 | Aug 15, 2021 | CHRISTUS Health, Pharco Pharmaceuticals |
| NCT01141556 | Phase 3 | Dec 1, 2010 | University of Bern |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| American Regent, Inc. | For profit | 2 | 2 | 1 | 2023 |
| CHRISTUS Health | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Pharco Pharmaceuticals | For profit | 1 | 0 | 1 | 2021 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2010 |
Marketing (13)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Regent, Inc. | For profit | NDA | Apr 30, 2019 |
| Apicore | For profit | MKTG | Dec 31, 2025 |
| Aspiro | For profit | MKTG | Jun 11, 2025 |
| BPI | For profit | MKTG | Jan 7, 2026 |
| Cipla | For profit | MKTG | Jul 21, 2025 |
| Daiichi Sankyo | For profit | NDA2 | Apr 30, 2019 |
| Fresenius | For profit | MKTG | Feb 10, 2025 |
| Gland Pharma Ltd | For profit | MKTG | Jul 8, 2025 |
| KINDOS | For profit | MKTG | Feb 3, 2026 |
| STERISCIENCE | For profit | MKTG | Apr 28, 2025 |
| STIRA | For profit | MKTG | Dec 31, 2025 |
| Sankyo | For profit | MKTG | Apr 30, 2019 |
| Sun Pharmaceuticals | For profit | MKTG | Feb 20, 2025 |